Relationship Between PTEN and Glycemic Variability and Outcome in Critically Ill Patients (GLUPTEN)
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2014 by University of Roma La Sapienza.
Recruitment status was: Recruiting
Information provided by (Responsible Party):
Alessandro Laviano, University of Roma La Sapienza
First received: February 11, 2013
Last updated: December 4, 2014
Last verified: December 2014
Glycemic variability in critically ill patients is a recognized negative prognostic factor. The molecular mechanisms determining inter-patients variability in glucose metabolism during stress are not fully understood. The Phosphatase and Tensin homolog (PTEN) is known to influence glucose homeostasis by interfering in intracellular insulin signaling.
Aim of this study is to ascertain whether differential expression of PTEN in critically ill patients correlates with glycemic variability and clinical outcome.
||Observational Model: Case-Only
Time Perspective: Prospective
||Influence of PTEN on Glycemic Variability and Clinical Outcome in the Critically Ill Patient.
Primary Outcome Measures:
- Length of ICU stay [ Time Frame: Day 1 up to day 28 ]
Secondary Outcome Measures:
- Glycemic variability as expressed by standard deviation of the glycemia measurements [ Time Frame: Day 1 up to day 28 ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Primary Completion Date:
||December 2014 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years to 70 Years (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Truma patients admitted to general ICU
- provision informed consent
- impaired fasting glucose levels
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01796847
|University of Rome La Sapienza, University Hospital
|Rome, Italy, 00185 |
|Contact: Donatella Dell'Utri, MD firstname.lastname@example.org |
|Principal Investigator: Alessandro Laviano, MD |
University of Roma La Sapienza
||Alessandro Laviano, MD
||Sapienza University of Rome
||Alessandro Laviano, Associate Professor, University of Roma La Sapienza
History of Changes
|Other Study ID Numbers:
|Study First Received:
||February 11, 2013
||December 4, 2014
Keywords provided by University of Roma La Sapienza:
Length of stay
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on February 24, 2017
Glucose Metabolism Disorders